Use of Lubiprostone in Constipating Disorders and Its Potential for Opioid-Induced Bowel Dysfunction

Total Page:16

File Type:pdf, Size:1020Kb

Use of Lubiprostone in Constipating Disorders and Its Potential for Opioid-Induced Bowel Dysfunction DRUG EVALUATION Use of lubiprostone in constipating disorders and its potential for opioid-induced bowel dysfunction Lubiprostone is a novel medication, approved by the US FDA for the treatment of chronic idiopathic constipation in adults and constipation-predominant irritable bowel syndrome in adult women. It is an activator of the CIC-2 chloride channel, indirectly making more water available in the lumen of the gastrointestinal tract. Secondary stretching of the gastrointestinal wall possibly causes increased small- and large-bowel transit, making it beneficial in constipation-based conditions, not only chronic idiopathic constipation and constipation-predominant irritable bowel syndrome, but also possibly opioid-induced bowel dysfunction. Lubiprostone has some preclinical data to support its use in this indication, confirmed by the preliminary efficacy and safety results of the two, very recently completed, randomized, double-blind, placebo-controlled studies. KEYWORDS: chronic idiopathic constipation constipation-predominant Egilius LH Spierings irritable-bowel syndrome lubiprostone opioid-induced bowel dysfunction Department of Neurology, Brigham and Women’s Hospital, Harvard Medical Lubiprostone is a novel medication that, in in this case, of chloride ions, for which the School, and January 2006, was approved by the US FDA lipid-bilayer cell membrane is not permeable. It Craniofacial Pain Center, for the treatment of chronic idiopathic constipa- facilitates diffusion down a concentration gra- Department of General tion in adults, and in April 2008, was approved dient, which is created by the uptake of chloride Dentistry, Tufts University for the treatment of constipation-predominant ions into the cell across the basolateral mem- School of Dental Medicine irritable bowel syndrome (IBS) in adult women. brane through sodium–potassium–chloride 25 Walnut Street, This review will discuss lubiprostone’s pharma- cotransport activity. Suite 400, Wellesley Hills, cology, as well as its efficacy and safety in the In simplified terms, there are four types MA 02481-2150, USA approved indications; in addition the preclinical of chloride channels: voltage-gated, calcium- Tel.: +1 781 431 1113 and preliminary clinical efficacy and safety data gated, protein-kinase-gated and ligand-gated. Fax: +1 781 431 1086 supporting its potential usefulness in the treat- The CIC-2 channel, the selective target of [email protected] ment of opioid-induced bowel dysfunction will lubiprostone, is one of nine voltage-gated be presented. chloride channels. Activation of this channel results in an efflux of chloride ions from the Lubiprostone epithelial intracellular space into the lumen of Structure the gastro intestinal tract. The efflux of chloride ® Lubiprostone (SPI-211/RU-211, Amitiza ) [101] ions is followed by a flow of sodium ions from is a bicyclic fatty-acid derived from the 15-keto the gastro intestinal extracellular space through (FIGURE 1) metabolite of prostaglandin E1 . It is a paracellular pathways in between the epithelial member of a new class of compounds called pros- cells, to maintain electroneutrality. The accu- tones, a collective name for the 15-keto metabolites mulation of sodium ions in the gastrointestinal of natural prostaglandins and structurally similar lumen, in turn, draws extracellular water into compounds. The only other FDA-approved pros- the lumen to maintain osmotic balance. tone is unoprostone, indicated for the lowering of intraocular pressure in patients with open-angle Metabolism glaucoma or ocular hypertension. As a fatty acid, lubiprostone is highly lipophilic, but its absorption is negligible due to rapid Function metabolism locally in the gastrointestinal tract, Lubiprostone is an activator of the CIC-2 chlo- resulting in a bioavailability of less than 1%. Its ride channel, which is a transmembrane protein, main metabolite is M3 or 15-hydroxy-lubipros- located in the apical or luminal membrane of tone, which is pharmacologically active and does the epithelial cells lining the gastrointestinal get absorbed. However, its systemic bioavailabil- tract (FIGURE 2). The protein allows the passage, ity is also low, and accounts for less than 10% of 10.2217/THY.09.52 © 2009 Future Medicine Ltd Therapy (2009) 66(5),(5), 657–665 ISSN 1475-0708 657 DRUG EVALUATION Spierings Lubiprostone in opioid-induced bowel dysfunction DRUG EVALUATION also opioid-induced bowel dysfunction. The slow- O ing of gastric emptying, causing gastric disten- O H sion, may account for its most common adverse OH event, nausea. H An important function of the colon is to extract water from the stool; with the increased transit H the colon has less time to perform this function, O resulting in softer stool, which, in turn, is easier to evacuate. A schematic of lubi prostone’s mode of HO action in relieving constipation-based conditions F is shown in FIGURE 3. F CH3 From a safety perspective, the studies in healthy volunteers have shown lubiprostone not to affect Figure 1. Lubiprostone. serum electrolytes and not to impact the elec- trocardiogram, which was also confirmed in the the administered lubiprostone dose. It has a time studies of lubiprostone in subjects with chronic to maximum plasma concentration and plasma- constipation and constipation-predominant IBS elimination half-life of approximately 1 h; its reviewed below. protein binding is 94%. Chronic idiopathic constipation Mode of action Definition In healthy volunteers, lubiprostone has been Rome III refers to chronic idiopathic constipa- shown to decrease gastric emptying and increase tion as functional constipation that presents as small-bowel and large-bowel transit [1], but not to persistently difficult, infrequent or seemingly increase colonic motor function [2]. The motility incomplete defecation, not meeting IBS crite- effects that occur with lubiprostone are secondary ria [3]. It estimates constipation to occur in up to the secretion of water it causes into the lumen of to 27% of the population, affecting all ages, and the gastrointestinal tract. The increased water, in to be most common in women and nonwhites. turn, distends the gastro intestinal tract and causes The diagnostic criteria listed for functional mural stretching, delaying gastric emptying to constipation require them to be fulfilled for facilitate digestion and accelerating bowel transit the last 3 months, with symptom onset at least to facilitate stool evacuation. The latter makes the 6 months prior to diagnosis: medication beneficial in constipation-based con- Must include two or more of the following: ditions, such as chronic idiopathic constipation, constipation-predominant IBS and, potentially, – Straining during at least 25% of defecations – Hard or lumpy stools in at least 25% of Apical Basolateral defecations – Sensation of incomplete evacuation for at least 25% of defecations CFTR - Cl + Cl- channel K Cl- Na–K–2Cl – Sensation of anorectal obstruction or Na+ cotransporter blockage for at least 25% of defecations Na+ ClC-2 - + Cl ~ Na pump – Manual maneuvers to facilitate in at least Cl- channel K+ 25% of defecations + K+ channel K – Fewer than three defecations per week Loose (mushy) or watery stools are rarely Na+ Paracellular path present without the use of laxatives There are insufficient criteria for IBS Figure 2. Chloride-ion (Cl-) transport in intestinal epithelial cells. At the basolateral membrane, chloride ions enter the cell from the blood across the In the above diagnostic criteria, hard or sodium–potassium–chloride (Na–K–2Cl) cotransporter. Sodium ions are expelled lumpy stools is defined as types 1 or 2 of the by the sodium pump and potassium ions leave via a potassium channel. Sodium Bristol Stool Form Scale – that is, separate ions are shown crossing the cell layer via a paracellular pathway, but sodium hard lumps like nuts (difficult to pass) or sau- channels also exist (not shown). Reproduced with permission from [11]. sage shaped but lumpy; loose (mushy) or watery 658 Therapy (2009) 6(5) future science group DRUG EVALUATION Spierings Lubiprostone in opioid-induced bowel dysfunction DRUG EVALUATION Lubiprostone Increased intraluminal chloride Increased intraluminal sodium Decreased Increased Softer stool water intraluminal absorption water Decreased Increased transit time intraluminal Easier volume evacuation Increased Luminal Easier motility distension evacuation Mural stretching Figure 3. Mode of action of lubiprostone in constipation-based conditions. stools are defined as types 6 or 7 on the Bristol 33 subjects were randomized to placebo, Stool Form Scale – that is, fluffy pieces with 30 subjects to 24-µg lubiprostone, 32 subjects ragged edges, a mushy or watery stool, no solid to 48-µg lubiprostone and 34 subjects to 72-µg pieces or entirely liquid. lubiprostone. A spontaneous bowel movement was defined as a bowel movement not preceded Lubiprostone within 24 h by intake of rescue medication, Dose exploration consisting of a 10-mg bisacodyl suppository or A randomized, double-blind, placebo-controlled a sodium-phosphate enema. The subjects also study evaluated lubiprostone in the treatment had to have abdominal bloating or discomfort of chronic idiopathic constipation in doses and one or more of the following symptoms: of 24, 48 and 72 µg per day, administered as (very) hard stool, subjectively incomplete evacu- 24 µg once-daily, twice-daily and three-times ation and straining at defecation. The eligibil- daily, respectively, for 3 weeks [4]. The study ity requirements
Recommended publications
  • Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review
    Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review (TCR) March 7, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. March 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004–2019 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) alosetron (Lotronex®)1 generic, .
    [Show full text]
  • Inflammatory Bowel Disease Irritable Bowel Syndrome
    Inflammatory Bowel Disease and Irritable Bowel Syndrome Similarities and Differences 2 www.ccfa.org IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 Important Differences Between IBD and IBS Many diseases and conditions can affect the gastrointestinal (GI) tract, which is part of the digestive system and includes the esophagus, stomach, small intestine and large intestine. These diseases and conditions include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 www.ccfa.org 3 Inflammatory bowel diseases are a group of inflammatory conditions in which the body’s own immune system attacks parts of the digestive system. Inflammatory Bowel Disease Inflammatory bowel diseases are a group of inflamma- Causes tory conditions in which the body’s own immune system attacks parts of the digestive system. The two most com- The exact cause of IBD remains unknown. Researchers mon inflammatory bowel diseases are Crohn’s disease believe that a combination of four factors lead to IBD: a (CD) and ulcerative colitis (UC). IBD affects as many as 1.4 genetic component, an environmental trigger, an imbal- million Americans, most of whom are diagnosed before ance of intestinal bacteria and an inappropriate reaction age 35. There is no cure for IBD but there are treatments to from the immune system. Immune cells normally protect reduce and control the symptoms of the disease. the body from infection, but in people with IBD, the immune system mistakes harmless substances in the CD and UC cause chronic inflammation of the GI tract. CD intestine for foreign substances and launches an attack, can affect any part of the GI tract, but frequently affects the resulting in inflammation.
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome Agents
    Therapeutic Class Overview Irritable Bowel Syndrome Agents Therapeutic Class Overview/Summary: This review will focus on agents used for the treatment of Irritable Bowel Syndrome (IBS).1-5 IBS is a gastrointestinal syndrome characterized primarily by non-specific chronic abdominal pain, usually described as a cramp-like sensation, and abnormal bowel habits, either constipation or diarrhea, in which there is no organic cause. Other common gastrointestinal symptoms may include gastroesophageal reflux, dysphagia, early satiety, intermittent dyspepsia and nausea. Patients may also experience a wide range of non-gastrointestinal symptoms. Some notable examples include sexual dysfunction, dysmenorrhea, dyspareunia, increased urinary frequency/urgency and fibromyalgia-like symptoms.6 IBS is defined by one of four subtypes. IBS with constipation (IBS-C) is the presence of hard or lumpy stools with ≥25% of bowel movements and loose or watery stools with <25% of bowel movements. When IBS is associated with diarrhea (IBS-D) loose or watery stools are present with ≥25% of bowel movements and hard or lumpy stools are present with <25% of bowel movements. Mixed IBS (IBS-M) is defined as the presence of hard or lumpy stools with ≥25% and loose or water stools with ≥25% of bowel movements. Final subtype, or unsubtyped, is all other cases of IBS that do not fall into the other classes. Pharmacological therapy for IBS depends on subtype.7 While several over-the-counter or off-label prescription agents are used for the treatment of IBS, there are currently only two agents approved by the Food and Drug Administration (FDA) for the treatment of IBS-C and three agents approved by the FDA for IBS-D.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • Amitiza (Lubiprostone) Capsule, 24 Mcg and 8 Mcg
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: NDA 021908/S-010 Trade Name: AMITIZA Generic Name: Lubiprostonel Sponsor: Sucampo Pharma Americas, Inc. Approval Date: 11/26/2012 Indications: Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults (1.1) Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old (1.2) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021908/S-010 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters Labeling X Summary Review Officer/Employee List Office Director Memo Cross Discipline Team Leader Review Medical Review(s) Chemistry Review(s) Environmental Assessment Pharmacology Review(s) X Statistical Review(s) Microbiology Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) Risk Assessment and Risk Mitigation Review(s) Proprietary Name Review(s) Other Review(s) Administrative/Correspondence Document(s) X CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021908/S-010 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 21908/S-010 SUPPLEMENT APPROVAL Sucampo Pharma Americas, Inc. Attention: Jeff Carey Senior Director, Regulatory Affairs 4520 East-West Highway, Suite 300 Bethesda, Maryland 20814 Dear Mr. Carey: Please refer to your Supplemental New Drug Application (sNDA) dated and received March 7, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Amitiza (lubiprostone) Capsule, 24 mcg and 8 mcg. We acknowledge receipt of your amendment dated May 8, 2012. This Prior Approval supplemental new drug application provides for the following: • Removal of Section 5.1 Pregnancy • Revisions to Section 8.1 Pregnancy and Section 8.3 Nursing Mothers • Addition of Section 17.2 Nursing Mothers We have completed our review of this supplemental application, as amended.
    [Show full text]
  • Identification of Pparγ Ligands with One-Dimensional Drug Profile Matching
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Identification of PPARγ ligands with One-dimensional Drug Profile Matching Diána Kovács1 Introduction: Computational molecular database screening helps to decrease the time and Zoltán Simon2,3 resources needed for drug development. Reintroduction of generic drugs by second medical Péter Hári2,3 use patents also contributes to cheaper and faster drug development processes. We screened, András Málnási-Csizmadia2,4,5 in silico, the Food and Drug Administration-approved generic drug database by means of the Csaba Hegedűs6 One-dimensional Drug Profile Matching (oDPM) method in order to find potential peroxisome László Drimba1 proliferator-activated receptor gamma (PPARγ) agonists. The PPARγ action of the selected generics was also investigated by in vitro and in vivo experiments. József Németh1 Materials and methods: The in silico oDPM method was used to determine the binding Réka Sári1 potency of 1,255 generics to 149 proteins collected. In vitro PPARγ activation was determined 1 Zoltán Szilvássy by measuring fatty acid-binding protein 4/adipocyte protein gene expression in a Mono Mac 1 Barna Peitl 6 cell line. The in vivo insulin sensitizing effect of the selected compound (nitazoxanide; 1Department of Pharmacology 50–200 mg/kg/day over 8 days; n = 8) was established in type 2 diabetic rats by hyperinsulinemic and Pharmacotherapy, University euglycemic glucose clamping. of Debrecen, Debrecen, Hungary; 2Drugmotif, Ltd, Veresegyház, Hungary; Results: After examining the closest neighbors of each of the reference set’s members and 3Printnet, Ltd, Budapest, Hungary; counting their most abundant neighbors, ten generic drugs were selected with oDPM.
    [Show full text]
  • Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-Mediated Pathway
    Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Chan, Walter W., and Hiroshi Mashimo. 2013. “Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway.” Journal of Neurogastroenterology and Motility 19 (3): 312-318. doi:10.5056/ jnm.2013.19.3.312. http://dx.doi.org/10.5056/jnm.2013.19.3.312. Published Version doi:10.5056/jnm.2013.19.3.312 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717596 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA J Neurogastroenterol Motil, Vol. 19 No. 3 July, 2013 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm.2013.19.3.312 Original Article JNM Journal of Neurogastroenterology and Motility Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway Walter W Chan1,2 and Hiroshi Mashimo1,2,3* 1Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, MA, USA; 2Harvard Medical School, Boston, MA, USA; and 3Division of Gastroenterology, VA Boston Health System, Boston, MA, USA Background/Aims Lubiprostone, a chloride channel type 2 (ClC-2) activator, was thought to treat constipation by enhancing intestinal secretion.
    [Show full text]
  • Cytarabine Analogues by Ion-Pairing LC-MS/MS
    © Advanced Chromatography Technologies Ltd. 1 ® ACE HPLC / UHPLC Columns www.ace-hplc.com Cytarabine Analogues by Ion-Pairing LC-MS/MS Cytarabine and cytidine are isobaric. Robust method with good separation achieved. LLOQ = 1 ng/ml human plasma ACE 3 C18 3μm, 50 x 2.1 mm Gradient analysis A = 0.1% perfluoropentanoic acid + 0.1% formic acid in water B = 0.1% perfluoropentanoic acid + 0.1% formic acid in acetonitrile T (mins) %B 0 0 0.5 0 3.0 13 4.0 90 5.0 0 Flow rate: 0.7 ml/min API 4000 MS TurboIonSpray, positive mode Source temperature: 550°C Reproduced with permission of Agilux Laboratories, USA © Advanced Chromatography Technologies Ltd. 2 ® ACE HPLC / UHPLC Columns www.ace-hplc.com Tricyclic Antidepressants Key: ACE Excel SuperC18 1 Doxepin 2μm, 100 x 3.0mm 1a Doxepin isomer Gradient analysis 1 Imipramine 3 A = 20 mM ammonium formate pH 3.0 2 Desipramine 3 Amitriptyline B = 20 mM ammonium formate pH 3.0 in MeOH:water 9:1 v/v 4 Nortriptyline 1 5 Clomipramine 2 Time (mins) %B 6 0 50 6 70 7 70 7.5 4 5 Flow rate: 1.2ml/min Column temperature: 40°C Injection volume: 2μl Detection: UV, 260nm 1a 1 2 3 4 5 6 7 min © Advanced Chromatography Technologies Ltd. 3 ® ACE HPLC / UHPLC Columns www.ace-hplc.com 15-Hydroxy Lubiprostone in Human Plasma Lubiprostone, a fatty acid derived from prostaglandin E1, is rapidly metabolised to 15-hydroxy lubiprostone. Quantitation is based on 15-hydroxy lubiprostone, with the d4 analogue as internal standard Lowest calibration standard sample containing 2.0pg/ml in human 15-Hydroxy lubiprostone EDTA K3 plasma MW 392.5 ACE Excel 2 C18 2μm, 50 x 3.0mm Isocratic analysis 15-Hydroxy I.S.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Interactions with HBV Treatment
    www.hep-druginteractions.org Interactions with HBV Treatment Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 1 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF. ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Anaesthetics & Muscle Relaxants Antibacterials (continued) Bupivacaine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisatracurium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapsone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoflurane ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Delamanid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ketamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ertapenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nitrous oxide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Erythromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Propofol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethambutol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiopental ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flucloxacillin ◆ ◆ ◆ ◆ ◆ ◆ Tizanidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gentamicin ◆ ◆ ◆ ◆ ◆ ◆ Analgesics Imipenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aceclofenac ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoniazid ◆ ◆ ◆ ◆ ◆ ◆ Alfentanil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aspirin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Linezolid ◆ ◆ ◆ ◆ ◆ ◆ Buprenorphine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lymecycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Celecoxib ◆ ◆ ◆ ◆ ◆ ◆ ◆ Meropenem ◆ ◆ ◆ ◆ ◆ ◆ Codeine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for Methenamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dexketoprofen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Metronidazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dextropropoxyphene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moxifloxacin ◆ ◆ ◆
    [Show full text]
  • 2015.09 IBS Drug Class Review.Pdf
    Drug Class Review Agents Indicated in the Treatment of Irritable Bowel Syndrome 56:92 GI Drugs, Miscellaneous Alosetron (Lotronex®) Eluxadoline (Viberzi®) Linaclotide (Linzess®) Lubiprostone (Amitiza®) Tegaserod (Zelnorm®) Final Report September 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Irene Pan, PharmD Candidate 2016 Chelsey Hancock, PharmD Candidate 2016 Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. 1 Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Comparison of the Agents Indicated in the Treatment of IBS ................................. 5 Disease Overview ........................................................................................................................ 6 Table 2. Summary of IBS Treatment Options ........................................................................ 8 Table 3. IBS Disease Staging System .................................................................................... 11 Table 4. Most Current Clinical Practice Guidelines for the Treatment of IBS ..................... 13 Pharmacology ..............................................................................................................................
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]